Two New β3 Integrin Mutations in Indian Patients with Glanzmann Thrombasthenia: Localization of Mutations Affecting Cysteine Residues in Integrin β3

Sona Nair; Jihong Li; W. Beau Mitchell; Dipika Mohanty; Barry S. Coller; Deborah L. French

doi:10.1055/s-0037-1613244

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2002; 88(03): 503-509
DOI: 10.1055/s-0037-1613244

Review Article

Schattauer GmbH

Two New β3 Integrin Mutations in Indian Patients with Glanzmann Thrombasthenia: Localization of Mutations Affecting Cysteine Residues in Integrin β3

Sona Nair

²Institute of Immunohaematology, Mumbai, India

,

Jihong Li

¹Department of Medicine, Mount Sinai School of Medicine, New York, NY

,

W. Beau Mitchell

¹Department of Medicine, Mount Sinai School of Medicine, New York, NY

,

Dipika Mohanty

²Institute of Immunohaematology, Mumbai, India

,

Barry S. Coller

¹Department of Medicine, Mount Sinai School of Medicine, New York, NY

,

Deborah L. French

¹Department of Medicine, Mount Sinai School of Medicine, New York, NY

› Institutsangaben

Abstract

Summary

New mutations in the β3 integrin subunit have been identified in two unrelated Glanzmann thrombasthenia patients originating from India and Bangladesh. Both patients had histories of excessive bleeding and were found to have Glanzmann thrombasthenia based on absent ADPinduced platelet aggregation. Immunoblotting of platelet lysates of Patient 1 demonstrated reduced levels of αIIb and an unexpected high Mr β3 band of ∼260,000, with little or no normal-sized β3. Upon reduction, a weak β3 band of normal Mr was observed. Platelet lysates of Patient 2 demonstrated undetectable levels of β3. Sequence analyses identified homozygous mutations in the β3 genes of both patients. Patient 1 had a C506Y missense mutation resulting in the expression of an unpaired cysteine; we propose that the Mr ∼260,000 band is a disulfide-bonded β3 dimer. Patient 2 had an insertion mutation resulting in a frameshift and premature termination. Both mutations affect biogenesis of platelet αIIbβ3 receptors.

This work was supported in part by grants HL19278 (B.S.C.), AHA Heritage Affiliate, Ilma F. Kern Foundation in honor of Jonathan Halperin, MD (D.L.F.), The Charles Slaughter Foundation (D.L.F.), and a fellowship from an Institutional NRSA, NHLBI T32 HL07824-06 (to W.B.M.)

Keywords

Platelets - αIIbβ3 - Glanzmann thrombasthenia

Volltext

Referenzen

References
1 George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: The spectrum of clinical disease. Blood 1990; 75: 1383-95.
2 French DL. The molecular genetics of Glanzmann’s thrombasthenia. Platelets 1998; 09: 5-20.
3 Seligsohn U, Rososhansky S. A Glanzmann’s thrombasthenia cluster among Iraqi Jews in Israel. Thromb Haemost 1984; 52: 230-1.
4 Khanduri U, Pulimood R, Sudarsanam A. et al. Glanzmann’s thrombasthenia. A review and report of 42 cases from South India. Thromb Haemost 1981; 46: 717-21.
5 Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci USA 1991; 88: 3160-4.
6 Rosenberg N, Yatuv R, Orion Y. et al. Glanzmann thrombasthenia caused by an 11.2-kb deletion in the glycoprotein IIIa (β3) is a second mutation in Iraqi Jews that stemmed from a distinct founder. Blood 1997; 89: 3654-62.
7 Yatuv R, Rosenberg N, Zivelin A. et al. Identification of a region in glycoprotein IIIa involved in subunit association with glycoprotein IIb: further lessons from Iraqi-Jewish Glanzmann thrombasthenia. Blood 2001; 98: 1063-9.
8 Schlegel N, Gayet O, Morel-Kopp MC. et al. The molecular genetic basis of Glanzmann’s thrombasthenia in a Gypsy population in France: Identification of a new mutation on the αIIb gene. Blood 1995; 86: 977-82.
9 Peretz H, Srivastava A, Usher S. et al. Prevention of Glanzmann thrombasthenia in Southern India by haplotype analysis and mutation identification (Abstract). Blood 1998; 92: 35a.
10 Saraya AK, Saxena R, Dhot PS, Choudhry VP, Pati H. Platelet function disorders in northern India. Natl Med J India 1994; 07: 5-7.
11 Coller BS, Seligsohn U, Zivelin A. et al. Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel: comparison of techniques for carrier detection. Br J Haematol 1986; 62: 723-35.
12 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: Additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983; 61: 99-110.
13 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
14 Coller BS. A new murine monoclonal antibody reports an activationdependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-8.
15 Knight DM, Wagner C, Jordan R. et al. Humanizing the constant region of the 7E3 murine monoclonal Fab antibody fragment reduces the immunogenicity of the variable region in humans. Mol Immunol 1995; 32: 1271-81.
16 Cheresh DA, Spiro RC. Biosynthetic and functional properties of an arg-gly-asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 1987; 262: 17703-11.
17 Coller BS, Seligsohn U, Little PA. Type I Glanzmann thrombasthenia patients from the Iraqi-Jewish and Arab populations in Israel can be differentiated by platelet glycoprotein IIIa immunoblot analysis. Blood 1987; 69: 1969-703.
18 Kutok JL, Coller BS. Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: Requirement for antibody bivalency. Thromb Haemost 1994; 72: 964-72.
19 Cieutat AM, Grimaldi CM, Chen FP, Wu C, Weiss HJ, Coller BS, French DL. Glycoprotein IIb Leu214Pro mutation produces Glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood 1998; 91: 1562-71.
20 Shadle PJ, Ginsberg MH, Plow EF, Barondes SH. Platelet-collagen adhesion: Inhibition by a monoclonal antibody that binds glycoprotein IIb. J Cell Biol 1984; 99: 2056-60.
21 Ginsberg MH, Lightsey A, Kunicki TJ. et al. Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann’s thrombasthenia. J Clin Invest 1986; 78: 1103-11.
22 Xiong J-P, Stehle T, Diefenbach B. et al. Crystal structure of the extracellular segment of integrin alphaVbeta3. Science 2001; 294: 339-45.
23 Beglova N, Blacklow SC, Takagi J, Springer TA. Cysteine-rich module structure reveals fulcrum for integrin rearrangement upon activation. Nature Struc Biol 2002; 09: 282-7.
24 Ruan J, Schmugge M, Clemetson KJ. et al. Homozygous Cys542→Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann’s thrombasthenia. Br J Haematol 1999; 105: 523-31.
25 Wilcox DA, Olsen JC, Ishizawa L. et al. Megakaryocyte-targeted synthesis of the integrin beta3-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood 2000; 95: 3645-52.
26 Grimaldi CM, Chen FP, Scudder LE, Coller BS, French DL. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (β3) in a Chinese patient with Glanzmann’s thrombasthenia. Blood 1996; 88: 1666-75.
27 Milet-Marsal S, Breillat C, Peyruchaud C. et al. Two different beta3 cysteine substitutions alter alphaIIbbeta3 maturation and result in Glanzmann thrombasthenia. Thromb Haemost 2002; 88: 104-10.
28 Ambo H, Kamata T, Handa M. et al. Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem Biophys Res Comm 1998; 251: 763-8.
29 Ruiz C, Liu CY, Sun QH. et al. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001; 98: 2432-41.
30 Chen P, Melchior C, Brons NHC. et al. Probing conformation changes in the I-like domain and the cysteine-rich repeat of human beta3 integrins following disulfide bond disruption by cysteine mutations. J Biol Chem 2001; 276: 38628-35.
31 Santoso S, Kalb R, Kroll H. et al. A point mutation leads to an unpaired cysteine residue and a molecular weight polymorphism of a functional platelet β3 integrin subunit. J Biol Chem 1994; 269: 8439-44.
32 Valentin N, Visentin GP, Newman PJ. Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: Evidence for heterogeneity in the humoral response. Blood 1995; 85: 3028-33.
33 Wang R, Shattil SJ, Ambruso DR, Newman PJ. Truncation of the cytoplasmic domain of β3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin αIIbβ3 complex. J Clin Invest 1997; 100: 2393-403.
34 Wang R, Peterson J, Aster RH, Newman PJ. Disruption of a long-range disulfide bond between Cys406 and Cys655 in glycoprotein IIIa does not affect the function of platelet glycoprotein IIb-IIIa. Blood 1997; 90: 1718-9.
35 Essex D, Li M. Protein disulfide isomerase mediates platelet aggregation and secretion. Br J Haematol 1999; 104: 448-54.
36 Lahov J, Gofer-Dadosh N, Luboshitz J, Hess O, Shaklai M. Protein disulfide isomerase mediates integrin-dependent adhesion. FEBS Letters 2000; 475: 89-92.
37 O’Neill S, Robinson A, Deering A. et al. The platelet integrin alphaIIbbeta3 has an endogenous thiol isomerase activity. J Biol Chem 2000; 275: 36984-90.
38 Yan B, Smith JW. A redox site involved in integrin activation. J Biol Chem 2000; 275: 39964-72.
39 Essex DW, Li M, Miller A, Feinman RD. Protein disulfide isomerase and sulfhydryl-dependent pathways in platelet activation. Biochemistry 2001; 40: 6070-5.
40 Zucker MB, Masiello NC. Platelet aggregation caused by dithiothreitol. Thromb Haemost 1984; 51: 119-24.
41 Peerschke EI. Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets. Thromb Haemost 1995; 73: 862-7.
42 Wippler J, Kouns WC, Schlaeger E-J. et al. The integrin αIIb-β3, platelet glycoprotein IIb-IIIa, can form a functionally active heterodimer complex without the cysteine-rich repeats of the β3 subunit. J Biol Chem 1994; 269: 8754-61.
43 Liu CY, Sun QH, Wang R, Paddock CM, Newman PJ. Disruption of the long-range GPIIIa Cys5-Cys435 disulfide bond results in the production of a constitutively active GPIIb-IIIa integrin complex (Abstract). Blood 1997; 90: 573a.
44 Liu C-Y, Sun Q-H, Wang R, Paddock CM, Newman PJ. Further examination of the role of GPIIIa long-range Cys5-Cys435 disulfide bond in conformational changes of GPIIb-IIIa: Substitution of cysteine 5 with alanine results in the production of a constitutively active GPIIb-IIIa integrin complex (Abstract). Blood 1998; 92: 344a.
45 Kashiwagi H, Tomiyama Y, Tadokoro S. et al. A mutation in the extracellular cysteine-rich repeat region of the β3 subunit activates integrins αIIbβ3 and αvβ3. Blood 1999; 93: 2559-68.
46 Yan B, Hu DD, Knowles SK, Smith JW. Probing chemical and conformational differences in the resting and active conformers of platelet integrin alphaIIbbeta3. J Biol Chem 2000; 275: 7249-60.
47 Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Human Mol Genet 1999; 08: 1893-900.
48 Brodsky JL, McCracken AA. ER-associated and proteasome-mediated protein degradation: how two topologically restricted events came together. Trends in Cell Biol 1997; 07: 151-6.
49 Zimrin AB, Gidwitz S, Lord S. et al. The genomic organization of platelet glycoprotein IIIa. J Biol Chem 1990; 265: 8590-5.
50 Villa-Garcia M, Li L, Riely G, Bray PF. Isolation and characterization of a TATA-less promoter for the human β3 integrin gene. Blood 1994; 83: 668-76.